| rivaroxaban / Generic mfg. |
2013-004484-31: Rivaroxaban and PCC: Prothrombin Complex Concentrate (Beriplex®) in patients with bleeding complications related to Rivaroxaban (Xarelto®) Rivaroxaban und PCC: Die Wirksamkeit von Prothrombin Komplex Kontentraten (Beriplex®) bei Patienten mit Blutungskomplikationen unter der Therapie mit Rivaroxaban (Xarelto®) |
|
|
| Ongoing | 4 | 20 | Europe | Tablet, Powder and solvent for solution for infusion, Xarelto, Beriplex | Medizinische Universität Innsbruck / Allg. u. chirug. Intensivmedizin, Medizinische Universität Innsbruck, CSL Behring | blood coagulation disorder Blutgerinnungsstörungen, treatment of bleeding Behandlung von Blutungen, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2016-002353-38: Optimal anticoagulation for patients with an increased risk for stroke after treatment of an heart arrhythmia (atrial fibrillation) by catheter ablation Optimale Gerinnungshemmung für Patienten mit einem erhöhten Risiko für Schlaganfall nach der Behandlung der Herzarrhythmie Vorhofflimmern durch Katheterablation |
|
|
| Not yet recruiting | 4 | 1572 | Europe | Xarelto, acetylsalicylic acid, Film-coated tablet, Tablet, Xarelto, acetylsalicylic acid of any trade name | Ottawa Heart Institute Research Corporation (OHIRC), Ottawa Heart Institute, Canadian Institute for Health Research, Biotronik Inc., Bayer Inc., Biotronik Inc. Canada | risk of stroke by atrial fibrillation durch Vorhofflimmern erhöhtes Schlaganfallrisiko, increased risk for stroke by atrial fibrillation, a heart arrhythmia durch Vorhofflimmern (eine Arrhythmie des Herzen) erhöhtes Risiko für Schlaganfall, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2017-000393-11: Blood thinners for frail elderly with a heart rhythm disorder |
|
|
| Ongoing | 4 | 2750 | Europe | Capsule, hard, Film-coated tablet, Tablet, Dabigatran ( Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Lixiana), acenocoumarol (Sintrom), fenprocumon (Marcoumar) | University Medical Center utrecht, ZonMw, Boehringer-Ingelheim, Bayer Healthcare, BMS Pfizer, Daiichi Sankyo | Atrial Fibrilation, heart rhythm disorder, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2018-001845-15: Evaluation of how well rivaroxaban is absorbed in patients with short bowel syndrom, based on laboratory markers and clinical outcomes such as thrombosis and bleeding. |
|
|
| Ongoing | 4 | 30 | Europe | Xarelto, Capsule, hard, Xarelto | Academic medical centre, department of internal medicine, Academic Medical centre, department of internal medicine | Chronic intestinal failuyre (IF) is caused by large surgical bowel resection, severe motility, or absorption diseorders. These patientds require partial or total parenteral nutrition (PN and TPN, respectively) and are thereby critically dependent on maintaining venous acces withj central venous catheter (CVC). CVC-related thrombosis is a frequent and serious complication that leads to catheter failure and is associated with CVC-infections and sepsis., Parenteral nutrition via central venous catheter is essential in patients unable to receive nutrition by oral intake or enteral tube feeding. Catheter-thrombosis is an important complication., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2018-003299-11: Can additional treatment with a third blood thinning medication reduce the risk of further clots in heart arteries, in patients with a recent heart attack who are already taking two blood thinning medications. |
|
|
| Not yet recruiting | 4 | 150 | Europe | Rivaroxaban, Clopidogrel, Ticagrelor, Tablet, Film-coated tablet, Rivaroxaban, Clopidogrel, Ticagrelor | East and North Hertfordshire NHS Trust, Bayer PLC | Acute Coronary Syndrome, Heart attack, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2019-001336-62: Anticoagulation for Stroke Prevention In patients with Recent Episodes of perioperative Atrial Fibrillation after noncardiac surgery - The ASPIRE-AF trial |
|
|
| Not yet recruiting | 4 | 2800 | Europe | ELIQUIS, PRADAXA, RIVAROXABAN, EDOXABAN TOSILATO, [B01AF02], [B01AE07], [B01AF01], [edoxaban], Tablet, Capsule, hard, Apixaban 2,5 mg filmovertrukne tabletter, Edoxaban 30 mg filmovertrukne tabletter, Apixaban 5 mg filmovertrukne tabletter, Edoxaban 60 mg filmovertrukne tabletter, Rivaroxaban 15 mg filmovertrukne tabletter, Rivaroxaban 20 mg filmovertrukne tabletter, Dabigatran 110 mg, hårde kapsler | Hamilton Health Sciences Corporation, Population Health Research Institute, Canadian Institute of Health Research, Population Health Reserarch Institute. | Perioperative atrial fibrillation after noncardiac surgery, Fast, irregular heartbeat after noncardiac surgery, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2014-005162-29: Treatment of thrombosis in the abdominal veins Behandeling van trombose in de buikvenen |
|
|
| Not yet recruiting | 4 | 100 | Europe | rivaroxaban, Tablet, rivaroxaban 20 mg | University of Insubria, Amsterdam UMC, location AMC | Splanchnic vein thrombosis (SVT) is an unusual site manifestation of venous thromboembolism (VTE). It includes the Budd-Chiari syndrome (BCS), portal vein thrombosis (PVT), mesenteric vein thrombosis (MVT) and splenic vein thrombosis (spVT). PVT is the most frequent manifestation of SVT, followed by MVT. Splanchische veneuze trombose (SVT) is wat locatie betreft een ongewoonlijke manifestatie van veneuze trombo-embolie (VTE). Het bevat de Budd-Chiari syndrome, vena porta trombose, vena mesenterica trombose en vena lienalis/splenica trombose., The condition called splanchnic vein thrombosis (SVT) which causes decreased blood flow through one of your splanchnic veins (portal, mesenteric, or splenic vein). d. Bij splanchnische veneuze trombose wordt obstructie veroorzaakt in 1 van de aderen van het maagdarmstelsel, hierdoor kan het zuurstofarme bloed niet meer goed verder kan stromen., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2020-001053-44: Stabilization of atherosclerosis in carotid artery by Rivaroxaban as evaluated by 3D ultrasound with contrast |
|
|
| Not yet recruiting | 4 | 62 | Europe | Film-coated tablet, Xarelto® | Rigshospitalet, Department of Vascular Surgery, Bayer AG | Patients with - Stable peripheral artery diseaseand- Asymptomatic, atherosclerotic plaque/stenosis in the carotid artery; asymptomatic regarding cerebral ischaemia including stroke and transient ischaemic attack (TIA) or amaurosis fugax. Patienter med - Stabil perifer arteriel sygdomog - Asymptomatisk, aterosklerotisk plaque/stenose in carotis; asymptomatisk vedr. iskæmisk apopleksi inkluderende stroke og transient cerebral iskæmi (TCI) eller amaurosis fugax., Patients with: - Atherosclerosis in limb arteries and - Atherosclerosis in carotid artery with no symptoms of major or minor stroke or temporary vision loss. Patienter med:- Åreforkalkning i underekstremitets blodkarog- Åreforkalkning i halspulsåren uden symptomer på slagtilfælde eller forbigående synstab., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT04059679: Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy |
|
|
| Recruiting | 4 | 30 | US | Rivaroxaban 2.5 Mg Oral Tablet, Aspirin 81 mg | LifeBridge Health, Janssen Scientific Affairs, LLC | Coronary Artery Disease, Peripheral Artery Disease | 03/21 | 08/21 | | |
2016-002291-27: Randomized trial of aspirin versus rivaroxaban after replacement of the aortic valve with a biological valve prosthesis Randomiseret forsøg med Aspirin over for Rivaroxaban efter udskiftning af aortaklap med en biologisk proteseklap |
|
|
| Not yet recruiting | 4 | 1000 | Europe | Anticoagulant and preservative solution for blood, Xarelto, Aspirin | Aalborg University Hospital, Bayer Pharma AG | Aortic valve stenosis Aortaklapstenose, Stenosis of the aortic valve Forsnævring af aortaklappen, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2020-000353-26: Clinical Surveillance vs. Anticoagulation for Low-risk Patients with Isolated Subsegmental Pulmonary Embolism: A Multicenter Randomized Placebo-Controlled Non-Inferiority Trial |
|
|
| Not yet recruiting | 4 | 276 | Europe | Rivaroxaban, Rivaroxaban, Tablet, Xarelto (Rivaroxaban) | Bern University Hospital, Swiss National Science Foundation, Bayer AG | Isolated subsegmental pulmonary embolism, Small blood clots in the pulmonary arteries, so called isloated pulmonary embolism., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2019-003679-20: The effect of rivaroxaban with aspirin on improving the vascular function in patients with lower extremity arterial disease. |
|
|
| Not yet recruiting | 4 | 330 | Europe | Tablet, Xarelto, Aspirin | Radboudumc, Bayer B.V. | symptomatic or stable pheripheral artery disease, lower extremity arterial disease, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | | | | |
2017-000236-34: Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN): an international, multicentre, randomised-controlled, two-arm, assessor-blinded trial |
|
|
| Not yet recruiting | 4 | 2000 | Europe | ELIQUIS 5 MG COMPRESSE RIVESTITE CON FILM, PRADAXA 150 MG CAPSULE RIGIDE, XARELTO 20 MG COMPRESSE RIVESTITE CON FILM, LIXIANA 60 MG COMPRESSE RIVESTITE CON FILM, [041225145], [038451100], [038744189], [044315188], Film-coated tablet, Capsule, hard, Xarelto 20 mg film-coated tablets, Pradaxa 150 mg hard capsules, Lixiana 60 mg film-coated tablets, Eliquis 5 mg film-coated tablets | Inselspital (University Hospital) Bern, Insel Gruppe AG, Bern University Hospital, Department of Neurology, Swiss National Science Foundation, Swiss Heart Foundation, Stroke Association | Recurrent strokes in patients with atrial fibrillation who suffered an ischaemic stroke, Recurrent strokes in patients with atrial fibrillation who suffered an ischaemic stroke, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Recruiting | 4 | 48 | Europe | Rivaroxaban 20 MG, Warfarin | University Hospital, Angers, Bayer | Nonvalvular Atrial Fibrillation | 02/23 | 02/23 | | |
NCT04853719: Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients |
|
|
| Completed | 4 | 88 | RoW | Rivaroxaban 2.5 Mg Oral Tablet, Aspirin 100 Mg oral Tablet | Science Valley Research Institute, Bayer | Peripheral Artery Disease, Intermittent Claudication | 02/23 | 02/23 | | |
| Not yet recruiting | 4 | 78 | Europe | Rivaroxaban, cardioaspirin 100ml, [bay59-7939], [24840074], Tablet, Gastro-resistant tablet, XARELTO - 2,5 MG - COMPRESSE RIVESTITE CON FILM - USO ORALE - BLISTER (PP/ALU) - 56 COMPRESSE, CARDIOASPIRIN - 100 MG COMPRESSE GASTRORESISTENTI30 COMPRESSE | FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE, Bayer S.p.A. | type 2 diabetic patients with stable peripheral or carotid artery disease diabete mellito di tipo 2 e vasculopatia arteriosa periferica o carotidea stabile, na na, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2019-000794-23: AntiCoagulants et COGnition (essai ACCOG) : Essai contrôlé randomisé ensimple aveugle comparant les effets neurocognitifs du rivaroxaban parrapport à un antagoniste de la vitamine K AntiCoagulants et COGnition (essai ACCOG) : Essai contrôlé randomisé ensimple aveugle comparant les effets neurocognitifs du rivaroxaban parrapport à un antagoniste de la vitamine K |
|
|
| Not yet recruiting | 4 | 48 | Europe | Xarelto® 20mg (Rivaroxaban), COUMADINE® (warfarine), Coated tablet, Tablet, XARELTO® 20 mg, COUMADINE® | CHU ANGERS, CHU ANGERS, BAYER | fibrillation atriale non valvulaire fibrillation atriale non valvulaire, fibrillation atriale non valvulaire fibrillation atriale non valvulaire, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Completed | 4 | 21 | Europe | Rivaroxaban 20mg, Xarelto, Sotorasib 960mg, Lumykras | Radboud University Medical Center, Amgen | Drug Drug Interaction Study | 03/24 | 03/24 | | |
SAFE-SSPE, NCT04263038: Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism |
|
|
| Recruiting | 4 | 276 | Europe, Canada | Rivaroxaban, Placebo | Drahomir Aujesky, University of Bern, Schweizerischer Nationalfonds, Leiden University Medical Center, The Ottawa Hospital, Bayer | Pulmonary Embolism, Embolism, Embolism and Thrombosis, Lung Diseases, Cardiovascular Diseases, Respiratory Tract Diseases, Venous Thromboembolism, Anticoagulant-induced Bleeding, Bleeding | 05/26 | 05/26 | | |
| Terminated | 4 | 9 | Canada | tinzaparin, Rivaroxaban | Sunnybrook Health Sciences Centre, LEO Pharma, Sunnybrook Research Institute | Deep Vein Thrombosis, Post Thrombotic Syndrome | 01/24 | 01/24 | | |
WRAP, NCT05973188: Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial |
|
|
| Recruiting | 4 | 141 | RoW | Warfarin, Warfarin oral tablet, Rivaroxaban 20 MG Oral Tablet, Xcept, Apixaban 5mg or 2.5mg oral tablet, Apixaget | Peshawar Institute of Cardiology, Getz Pharma | Left Ventricular Thrombus | 06/24 | 06/24 | | |
SPIRIT, NCT05797376: Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque Inflammation |
|
|
| Recruiting | 4 | 92 | RoW | Rivaroxaban 2.5mg, Xarelto 2.5mg | Asan Medical Center, Bayer | Atherosclerosis of Artery, Coronary Artery Disease, Peripheral Arterial Disease, Carotid Stenosis | 12/24 | 06/25 | | |
OCEAN, NCT02168829: Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial |
|
|
| Active, not recruiting | 4 | 1284 | Europe, Canada, RoW | Rivaroxaban, Xarelto, Acetylsalicylic acid, Aspirin, ASA | Ottawa Heart Institute Research Corporation, Canadian Institutes of Health Research (CIHR), Bayer, Biotronik Canada Inc | Atrial Fibrillation, Stroke | 07/25 | 08/25 | | |
2016-000958-36: RIDTS Study - Rivaroxaban for the treatment of symptomatic Isolated Distal deep vein Thrombosis Studio RIDTS- Rivaroxaban per il trattamento delle trombosi profonde distali isolate sintomatiche |
|
|
| Ongoing | 3 | 1100 | Europe | RIVAROXABAN, [BAY 59-7939], Film-coated tablet, Xarelto 15 mg, Xarelto 20 mg | DIPARTIMENTO DI MEDICINA CLINICA E SPERIMENTALE, Bayer | SYMPTOMATIC ISOLATED DISTAL DEEP VEIN THROMBOSIS Trombosi Venose Distali Isolate sintomatiche, SYMPTOMATIC ISOLATED DISTAL DEEP VEIN THROMBOSIS Trombosi Venose Distali Isolate sintomatiche, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2015-005090-20: A comparison between rivaroxaban and placebo for the prevention of deep vein thrombosis or pulmonary embolism afetr laparoscpic surgery for colorectal cancer after initial heparin prophylaxis Confronto tra rivaroxaban e placebo per la prevenzione della trombosi venosa profonda e dell'embolia polmonare dopo chirurgia laparoscopica per neoplasia del colon e/o retto dopo la terapia iniziale con eparina |
|
|
| Ongoing | 3 | 646 | Europe | Rivaroxaban, [NA], Film-coated tablet, XARELTO - 10 MG COMPRESSE RIVESTITE CON FILM - USO ORALE - BLISTER (PVC/PVDC/ALU) 30 COMPRESSE | FONDAZIONE FADOI, Bayer-Italia | Prevention of venous thromboembolism after laparoscopic surgery for colorectal cancer Prevenzione del tromboembolismo venoso dopo chirurgia laparoscopica per neoplasia del colon-retto, Prevention of venous thrombosis and pulmonary embolism after laparoscopic surgery for colorectal cancer Prevenzione della trombosi venosa e dell'embolia, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Completed | 3 | 6667 | Canada, RoW | Colchicine, Interferon-Beta, Aspirin, Rivaroxaban | Population Health Research Institute, Bayer | Coronavirus, Severe Acute Respiratory Syndrome | 12/22 | 12/22 | | |
TRACK, NCT03969953: Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease |
|
|
| Recruiting | 3 | 2000 | Europe, Canada, RoW | Rivaroxaban 2.5 Mg Oral Tablet, Xarelto, Placebo | The George Institute, George Clinical Pty Ltd, Bayer, Centre Hospitalier Régional Universitaire de Nancy, King Abdullah International Medical Research Center | Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease | 06/27 | 12/27 | | |
|
BRAIN-AF, NCT02387229: Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF |
|
|
| Terminated | 3 | 1238 | Canada | Rivaroxaban, Xarelto, standard of care | Montreal Heart Institute, Canadian Stroke Prevention Intervention Network, The Montreal Health Innovations Coordinating Center (MHICC), Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma, Montreal Heart Institute Foundation, Canadian Institutes of Health Research (CIHR), Hewitt Foundation | ATRIAL FIBRILLATION | 05/24 | 05/24 | | |
CAPTIVA, NCT05047172: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis |
|
|
| Recruiting | 3 | 1683 | US | Ticagrelor + Aspirin, Brilinta, Rivaroxaban + Aspirin, Xarelto, Clopidogrel + Aspirin, Plavix, Risk Factor Management | University of Florida, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca | Intracranial Arteriosclerosis, Stroke | 05/27 | 05/27 | | |
2019-001723-12: Aspirin® plus rivaroxaban versus rivaroxaban alone for the prevention of venous stent thrombosis in patients with post-thrombotic syndrome (long-term condition associated with redness, swelling, leg pain, and ulcers as a results of deep vein thrombosis) |
|
|
| Not yet recruiting | 2 | 316 | Europe | Aspirin protect 100 mg, Film-coated tablet, Aspirin protect 100 mg | Universitätsspital Zürich, Klinik für Angiologie, Universitätsspital Zürich, Klinik für Angiologie, Bayer (Schweiz) AG, BARD Medica S.A. | Post-thrombotic syndrome, Post-thrombotic syndrome is a long-term complication of a deep vein thrombosis. It may include following symptoms: pain, swelling, itching , red/brown skin discoloration and ulcer at the affected leg., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2020-004507-13: A study to compare how safe and well tolerated study drug Abelacimab (MAA868) is comapred to another drug called Rivaroxaban in patients with heart condition that causes an irregular and abnormally fast heart rate. |
|
|
| Not yet recruiting | 2 | 1200 | Europe, RoW | Abelacimab, Xarelto 15mg film-coated tablets, Xarelto 20mg film-coated tablets, MAA868, Concentrate for solution for injection, Film-coated tablet, Xarelto 15mg film-coated tablets, Xarelto 20mg film-coated tablets | Anthos Therapeutics, Anthos Therapeutics | Atrial Fibrillation, A heart condition that causes an irregular and abnormally fast heart rate., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2020-002282-33: Effect of anticoagulation therapy on clinical outcomes in COVID-19 (COVID-PREVENT) |
|
|
| Not yet recruiting | 2 | 400 | Europe | Xarelto, Film-coated tablet, Solution for injection, Solution for injection in pre-filled syringe, Xarelto | Charité - Universitaetsmedizin Berlin, Bayer AG, DZHK - Deutsches Zentrum für Herz-Kreislauf-Forschung | Patients with moderate to severe COVID-19 disease which may cause acute cardiac injury, Patients with moderate to severe COVID-19 disease which may cause acute cardiac injury, Diseases [C] - Virus Diseases [C02] | | | | |
ECRU, NCT05088928: Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care |
|
|
| Not yet recruiting | 2 | 40 | RoW | Apixaban, ECRU Tablets, Rivaroxaban, Rivascot tablets | Scotmann Pharmaceuticals, Rawalpindi Medical College | COVID-19 | 05/22 | 08/22 | | |
| Active, not recruiting | 2 | 1200 | Europe, Canada, US, RoW | Abelacimab, MAA868, Rivaroxaban | Anthos Therapeutics, Inc., The TIMI Study Group, Fortrea | Atrial Fibrillation (AF), Stroke | 12/23 | 12/25 | | |
|
| Completed | 2 | 272 | Europe | Rivaroxaban 10 MG Oral Tablet [Xarelto] | Insel Gruppe AG, University Hospital Bern, Bayer, Janssen Pharmaceuticals | Bariatric Surgery | 12/23 | 12/23 | | |
NCT06220123: A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery |
|
|
| Not yet recruiting | 2 | 350 | NA | SHR-2004, Enoxaparin Sodium Injection; Rivaroxaban Tablets | Beijing Suncadia Pharmaceuticals Co., Ltd | Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery | 06/25 | 07/25 | | |
NCT04729998: Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed Conditions |
|
|
| Not yet recruiting | 1 | 34 | RoW | Rivaroxaban film-coated tablet 20 mg, The test product, Xarelto® film-coated tablet 20 mg, The reference product | Pharmtechnology LLC, ClinPharmInvest, LLC | Bioequivalence | 02/21 | 02/21 | | |
NCT04753489: Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 10 mg in Healthy Male Volunteers in Fasting Conditions |
|
|
| Not yet recruiting | 1 | 34 | RoW | Rivaroxaban film-coated tablet 10 mg, The test product, Xarelto® film-coated tablet 10 mg, The reference product | Pharmtechnology LLC, ClinPharmInvest, LLC | Bioequivalence | 03/21 | 03/21 | | |
NCT05152420: Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects |
|
|
| Completed | 1 | 105 | Europe | VMX-C001, Placebo, Apixaban, Rivaroxaban, Edoxaban | VarmX B.V. | Coagulation Disorder | 02/23 | 02/23 | | |
NCT05723510: PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers |
|
|
| Completed | 1 | 87 | RoW | Tegoprazan 50mg, K-CAB Tab. 50 mg, Edoxaban 60mg, Lixiana Tab. 60mg, Apixaban 5mg, Eliquis Tab. 5 mg, Rivaroxaban 20mg, Xarelto Tab. 20 mg | HK inno.N Corporation | Healthy | 07/23 | 07/23 | | |
| Active, not recruiting | 1 | 24 | Europe | Apixaban 5 MG Tab, Edoxaban, Dabigatran, rivaroxaban, Dabigatran 150 MG Tab, Apixaban, Edoxaban, Rivaroxaban, Edoxaban 60Mg Tab, Apixaban, Dabigatran, Rivaroxaban, Rivaroxaban 20 MG Tab, Apixaban, Edoxaban, Dabigatran | Doasense GmbH | Anticoagulant Therapy | 12/23 | 12/23 | | |
| Recruiting | 1 | 48 | Europe | VMX-C001, Placebo, Rivaroxaban 20 mg Oral Tablet, Apixaban 5 mg Oral Tablet, Edoxaban 60 mg Oral Tablet | VarmX B.V. | Coagulation Disorder | 09/24 | 09/24 | | |
NCT06444178: Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants |
|
|
| Not yet recruiting | 1 | 224 | NA | Aspirin, REGN9933, REGN7508, Rivaroxaban | Regeneron Pharmaceuticals | Healthy Volunteers | 04/25 | 07/25 | | |
| Recruiting | N/A | 1200 | RoW | Rivaroxaban | Samsung Medical Center, Bayer | Atrial Fibrillation, Rivaroxaban, Elderly, Renal Insufficiency | 02/22 | 08/22 | | |
OSCAR SWE, NCT05150938: A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE) |
|
|
| Completed | N/A | 5737 | Europe | Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), vitamin K antagonist (VKA), other NOACs | Bayer, Janssen Research & Development, LLC | Treatment of Venous Thromboembolism in Cancer Patients | 02/23 | 02/23 | | |
NCT05546957: Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants |
|
|
| Completed | N/A | 60 | Europe | Aspirin, rivaroxaban low dose, rivaroxaban high dose | Regeneron Pharmaceuticals | Healthy Volunteer | 04/23 | 04/23 | | |
| Active, not recruiting | N/A | 1 | Europe | Apixaban, Rivaroxaban, Edoxaban, Dabigatran, VKA, LMWH | Pfizer | Neoplasms, Embolism | 12/24 | 12/24 | | |
XATOC, NCT04401761: A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the Legs |
|
|
| Completed | N/A | 3189 | Europe, RoW | Rivaroxaban (BAY59-7939, Xarelto), Xarelto, Acetylsalicylic acid, Aspirin | Bayer | Coronary Artery Disease, Peripheral Artery Disease | 06/23 | 09/23 | | |
REATTAIN, NCT04249401: Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) |
|
|
| Completed | N/A | 134897 | Europe | Rivaroxaban (Xarelto), Apixaban, Dabigatran, Warfarin | Bayer, Janssen, LP | Atrial Fibrillation | 09/23 | 09/23 | | |
STAR-D, NCT05093504: Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban |
|
|
| Terminated | N/A | 9 | US | Sham comparator, DrugSorb-ATR system, Sorbent hemoperfusion system | CytoSorbents, Inc | Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative | 01/24 | 01/24 | | |
TROMBIXDZ, NCT06184204: Observational Study:Safety,Efficacy and Quality of Life of Patients With Atrial Fibrillation, Treated With Trombix® |
|
|
| Active, not recruiting | N/A | 400 | RoW | Trombix® (Rivaroxaban), Trombix® | Beker Laboratories | Atrial Fibrillation | 12/24 | 04/25 | | |
NCT03772457: Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban |
|
|
| Recruiting | N/A | 400 | RoW | Rivaroxaban | Second Affiliated Hospital, School of Medicine, Zhejiang University, Bayer, Taizhou Hospital, Zhuji People's hospital, Shaoxing People's Hospital, Jinhua Central Hospital, HaiyanPeople's hospital, Wenzhou Central Hospital, The Central Hospital of Lishui City, Dongyang People's Hospital, Rui'an People's hospital | Cerebrovascular Stroke, Intracranial Hemorrhages, Anticoagulant, Matrix Metalloproteinases | 12/23 | 12/24 | | |
| Recruiting | N/A | 400 | RoW | Rivaroxaban | Seoul National University Hospital, Samjin Pharmaceutical Co., Ltd., Medtronic Korea Co., Ltd. | Atrial Fibrillation | 12/30 | 12/30 | | |
NCT06278051: An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism |
|
|
| Recruiting | N/A | 100 | Japan | Rivaroxaban granules for oral suspension, Xarelto, BAY59-7939, Warfarin | Bayer, Janssen Pharmaceutical Companies (formerly Johnson & Johnson Pharmaceutical Research & Development L.L.C.) | Venous Thromboembolism | 12/24 | 12/24 | | |
XARIN, NCT03887780: A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF) |
|
|
| Active, not recruiting | N/A | 504 | RoW | Rivaroxaban (Xarelto,Bay 59-7939) | Bayer, Janssen Research & Development, LLC | Non-valvular Atrial Fibrillation (NVAF) | 12/23 | 08/24 | | |
eVTE, NCT06232551: Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism |
|
|
| Not yet recruiting | N/A | 152000 | US | EHR (electronic health record) alert, No EHR (electronic health record) alert | Scott C. Woller, MD, Janssen Pharmaceuticals | Venous Thromboembolic Disease, Pulmonary Embolism and Thrombosis, Deep Vein Thrombosis, Hospitalism | 01/25 | 09/25 | | |
NCT04298567: Study to Learn More About the Safety and Effectiveness of Rivaroxaban (Xarelto) When Given Together With Acetylsalicylic Acid to Indian People With Narrowing of the Arteries of the Heart (CAD) and/or With Reduced Blood Flow in the Arteries of the Legs and Arms With Symptoms (Symptomatic PAD) |
|
|
| Completed | N/A | 300 | RoW | Rivaroxaban (Xarelto,Bay 59-7939), Acetylsalicylic acid(ASA) | Bayer | Prevention of Atherothrombotic Events, Coronary Artery Disease (CAD), Symptomatic Peripheral Artery Disease (Symptomatic PAD) | 03/24 | 06/24 | | |
SIFNOS, NCT05838664: A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France |
|
|
| Completed | N/A | 3691397 | Europe | No OAC, VKA, apixaban, rivaroxaban, dabigatran | Pfizer | Atrial Fibrillation | 03/24 | 03/24 | | |
NCT04694248: Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting |
|
|
| Recruiting | N/A | 172 | RoW | Rivaroxaban, Anticoagulant, Aspirin, Antiplatelet | First Affiliated Hospital of Zhejiang University, Zhejiang University, Ningbo No.2 Hospital, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, The Central Hospital of Lishui City, Taizhou Enze Hospital, Taizhou First People's Hospital, Boston Scientific Corporation | Deep Vein Thrombosis, Iliac Vein Thrombosis, Iliac Vein Obstruction, Iliac Vein Stenosis, Iliac Vein Compression Syndrome | 12/25 | 06/26 | | |
NCT06193863: An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure |
|
|
| Not yet recruiting | N/A | 50 | Japan | Rivaroxaban (Xarelto, BAY59-7939) | Bayer, Janssen Research & Development, LLC | Prevention of Venous Thromboembolism, Congenital Heart Disease, Fontan Procedure, Children | 06/26 | 12/26 | | |
| Recruiting | N/A | 1600 | Europe | dabigatran, rivaroxaban, apixaban or edoxaban, Pradaxa, Xarelto, Eliquis or Lixiana | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Daiichi Sankyo | Atrial Fibrillation, Recurrent Venous Thromboembolism | 08/24 | 08/24 | | |
HELIOS-AF, NCT05038228: High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France |
|
|
| Active, not recruiting | N/A | 1 | Europe | Apixaban, Rivaroxaban, Dabigatran, Vitamin K antagonist (VKA) | Pfizer | Atrial Fibrillation | 08/24 | 08/24 | | |
NCT02921022: Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma |
|
|
| Active, not recruiting | N/A | 110 | US | Gemcitabine, Nab-paclitaxel, PEGPH20 | Memorial Sloan Kettering Cancer Center, Halozyme Therapeutics, Miami Cancer Institute | Pancreatic Cancer, Advanced Pancreatic Ductal Adenocarcinoma | 10/25 | 10/25 | | |
| Enrolling by invitation | N/A | 100 | RoW | AngioJet device, Zalente, anticoagulation alone, rivaroxaban | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Boston Scientific Corporation | Acute Deep Venous Thrombosis of Femoral Vein (Disorder) | 06/25 | 06/25 | | |
| Recruiting | N/A | 300 | Europe, US | ClotTriever System, Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. | Inari Medical | Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome | 06/25 | 10/25 | | |
CORRAL-AF, NCT04684212: Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF |
|
|
| Not yet recruiting | N/A | 2931 | US | LAmbre PlusTM Left Atrial Appendage Closure System, LAmbre device, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa), OAC | Brian O'Neill MD, Lifetech Scientific (Shenzhen) Co., Ltd. | Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA | 12/29 | 12/34 | | |
XAPAEDUS, NCT05900388: A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE) |
|
|
| Not yet recruiting | N/A | 850 | Europe | Rivaroxaban (Xarelto, BAY59-7939), Standard of care (SOC) | Bayer, Janssen Research & Development, LLC | Venous Thromboembolism, Children Under 2 Years | 06/29 | 06/29 | | |
